Anti-fibrotic effect of aurocyanide, the active metabolite of auranofin.
- Published in:
- Archives of Pharmacal Research, 2023, v. 46, n. 3, p. 149, doi. 10.1007/s12272-023-01438-1
- By:
- Publication type:
- Article
Works matching IS 02536269 AND DT 2023 AND VI 46 AND IP 3
Results: 6
1
2
Cathepsin B maturation plays a critical role in leptin-induced hepatic cancer cell growth through activation of NLRP3 inflammasomes.
- Published in:
- Archives of Pharmacal Research, 2023, v. 46, n. 3, p. 160, doi. 10.1007/s12272-023-01437-2
- By:
- Publication type:
- Article
3
Engineered fibrotic liver-targeted truncated transforming growth factor β receptor type II variant for superior anti-liver fibrosis therapy.
- Published in:
- Archives of Pharmacal Research, 2023, v. 46, n. 3, p. 177, doi. 10.1007/s12272-023-01435-4
- By:
- Publication type:
- Article
4
Correction to: The multifaceted role of STAT3 pathway and its implication as a potential therapeutic target in oral cancer.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
5
Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
- Published in:
- Archives of Pharmacal Research, 2023, v. 46, n. 3, p. 131, doi. 10.1007/s12272-023-01433-6
- By:
- Publication type:
- Article
6
Naringin promotes fat browning mediated by UCP1 activation via the AMPK signaling pathway in 3T3-L1 adipocytes.
- Published in:
- Archives of Pharmacal Research, 2023, v. 46, n. 3, p. 192, doi. 10.1007/s12272-023-01432-7
- By:
- Publication type:
- Article